Monday, 7 August 2017

Novel Hepatitis Therapeutics for Revolutionary Treatment

Hepatitis is the inflammation of liver cells. It is caused due to excessive alcohol consumption, viral infection, autoimmune diseases, medication errors, nonalcoholic steatohepatitis, and toxins. Acute and chronic are the two basic categories of hepatitis. Acute hepatitis lasts for less than six months. If the condition persists even after six months then it is considered as chronic hepatitis. People with HCV-infected sexual partners, HIV infections, intranasal & injectable drug users, and recipients of infected blood products are at a high risk of hepatitis. Unhygienic conditions can also transmit this disease at a rapid pace.

HBV Infection & Its Causes

Hepatitis B Virus (HBV) infections can lead to several other liver diseases such as acute self-limited hepatitis, subclinical infection, and Chronic Hepatitis B (CHB) caused by continual infection. CHB can lead to liver cirrhosis and liver cancer. Both of these potentially lethal diseases are considered as some of the leading causes of deaths on the global scale.

A Revolutionary Cure for Hepatitis B

A new therapeutic vaccine “ABX2013” is said to transform the regular CHB treatment. This disease affects majority of global population and results in almost over a million deaths every year. This vaccine has reportedly shown considerably fewer adverse effects than other existing immunotherapeutic approaches. It is much easier to administer. This drug can control viral load for a longer time period. Viral load is the amount of hepatitis virus present in the blood of a person suffering from hepatitis.

Market Insights

According to a report by Grand View Research, Inc.; the global hepatitis therapeutics market is expected to witness high growth over the forecast period (2014 to 2025). Increasing number of various autoimmune diseases, high incidence of viral hepatitis, and rising healthcare expenditures and geriatric population can drive the global market in the years to come. Johnson & Johnson; Merck & Co., Inc.; AbbVie Inc.; and Bristol-Myers Squibb Company are some of the key companies operating in the worldwide market for hepatitis therapeutics.

In-Depth Research Report On Hepatitis Therapeutics Market:

No comments:

Post a Comment